Wallace M/LinkedIn
Jan 3, 2026, 14:08
Wallace M Shares a SWOT Analysis of Aqvesme’s FDA Approval
Wallace M, CEO and Founder of i3consult.com, shared on LinkedIn:
”FDA APPROVAL UPDATE: Aqvesme™ (mitapivat) for Thalassemia‑Related Anemia
The FDA approval of Aqvesme™ introduces the first oral, disease‑modifying therapy for anemia in adults with alpha‑ or beta‑thalassemia.
Our latest SWOT analysis explores the clinical significance and strategic implications of this milestone.
Read the full analysis.”
Stay updated with Hemostasis Today.
-
May 20, 2026, 17:10Applications are Now Open for the Fellowship in Clinical Haematology – Apollo Hospitals Navi Mumbai
-
May 20, 2026, 17:02Samantha Pasca and Deanna Maida on the Importance of Registries in Managing Hemophilia in Women
-
May 20, 2026, 16:48New Clinical Resources for Stroke Prevention – Anticoagulation Forum
-
May 20, 2026, 16:39Olivier Christophe: Colocalization of Factor X with Amyloid Light-Chain Deposits
-
May 20, 2026, 15:47Archil Jaliashvili: Hemopure and the Future of Oxygen Delivery in Severe Bleeding
-
May 20, 2026, 15:37Tareq Abadl։ Hemolysis in Blood Bags and Its Dangers in Transfusion
-
May 20, 2026, 15:27Kalyan Roy: Thalassaemia and the Importance of Early Screening
-
May 20, 2026, 15:11Adelard Kakunze: Changing the Future of Sickle Cell Disease in Africa
-
May 20, 2026, 15:00William Aird: When Oxygen Becomes the Limiting Factor